Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
PK Analysis Shows Benefit for rFVIII Product in Hemophilia A
Key clinical point: The recombinant factor VIII (rFVIII) product BAY 81‐8973 (Kovaltry) exhibited clinical benefits over sucrose‐formulated rFVIII‐FS (Kogenate) in patients with hemophilia A.
Major finding: Significant reductions were seen in annualized joint bleeding rate (P = .021), annualized bleeding rate (P = .038), and the number of spontaneous bleeds (P = .028) after switching to BAY 81-8973.
Study details: A comparative, cross-sectional, prospective study of 14 patients with moderate or severe hemophilia A.
Disclosures: The study was partially funded by an unrestricted grant from Bayer. The authors reported having no conflicts of interest.
Megías-Vericat JE et al. Haemophilia. 2019 Mar 13. doi: 10.1111/hae.13733.